Landmark BioVentures is an integrative corporate and drug development company using resources smartly to advance multiple innovative therapies. Anchored by foundational science, LBV uncovers hidden gems with unrealized therapeutic potential by connecting non-obvious dots and taking a strategically-focused active hands-on approach with each nexus company. Led by a seasoned multidisciplinary team of drug developers, entrepreneurs and deal makers, LBV harnesses its specialized and industry-relevant drug development expertise and opportunistic and creative deal-making in resource-constrained environments, to streamline drug development, focusing on holistic value creation and capture.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Bernouillistrasse 20, Basel,ch-4056,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- drug development, biotech, oncology, immuno-oncology, ophthalmology, immunology, pathobiology, inflammation, business development.
- HQ
- Basel
Landmark Bioventures Ag Questions
Landmark Bioventures Ag's website is https://www.landmarkbioventures.com/
Landmark Bioventures Ag's LinkedIn profile is https://ch.linkedin.com/company/landmark-bioventures
Landmark Bioventures Ag has
3 employees.
View email and phone details for 3
employees at Landmark Bioventures Ag.
Landmark Bioventures Ag's industry is
Biotechnology Research
Landmark Bioventures Ag's top competitors are
Kekkan Biologics,
G.clips Biotech,
Carla Biotherapeutics,
Spima Therapeutics,
Om Pharma,
Roca Therapeutics,
Elikya Therapeutics,
Massalia Therapeutics,
Biper Therapeutics,
Duhn Therapeutics.
Landmark Bioventures Ag's categories are Biotechnology Research
Landmark Bioventures Ag's founding year is 2021
